Cizzle Bio sharpens focus on earlier lung cancer detection

Cizzle Biotechnology Holdings plc

Love Your Lungs Week is a reminder that lung health depends on more than prevention. It also depends on better testing, clear medical conversations and earlier answers for people at higher risk.

Early detection is central to lung cancer outcomes. When cancer is found sooner, treatment can begin at a stage when it is more likely to be effective. That makes practical diagnostic tools an important part of improving the lung cancer pathway.

Cizzle Bio is advancing CIZ1B, a minimally invasive biomarker blood test for lung cancer. The test is being developed to support clinical decision-making alongside LDCT and other standard diagnostic approaches.

CIZ1B is being developed as a complementary tool that may help clinicians assess risk, guide next steps and support earlier investigation.

Love your lungs. Know your risk. Speak to your healthcare provider.

Cizzle Biotechnology Holdings plc (LON:CIZ) is a pioneering cancer diagnostics company, originally a spin-out from the University of York, and now listed on the London Stock Exchange.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Cizzle Bio expands CIZ1B lung cancer testing into San Antonio

Cizzle Bio expands the availability of its CIZ1B lung cancer blood test into San Antonio, adding to its existing...

Cizzle Biotechnology raises £500,000 to support US lung cancer test adoption

Cizzle Biotechnology has conditionally raised £500,000 from existing shareholder Frazer Lang to support the commercial adoption of its CIZ1B...

Cizzle Biotechnology to present CIZ1B lung cancer test advances at SYNLAB Symposium

Cizzle Biotechnology will present improvements to its CIZ1B lung cancer biomarker test at the SYNLAB Innovation Academy Symposium on...

Cizzle Biotechnology gains recognition for lung cancer test

Cizzle Biotechnology has been shortlisted for Best Non-Therapeutic R&D Company of the Year at the One Nucleus Genesis Conference,...

Cizzle Biotechnology revises US payments as lung cancer test rollout advances

Cizzle Biotechnology has agreed revised payment terms with Cizzle Bio Inc, deferring US$1.81 million in guaranteed advance payments to...

Cizzle Bio outlines clinical use and ordering process for CIZ1B lung cancer blood test

Cizzle Bio has outlined clinical applications and ordering procedures for its CIZ1B lung cancer blood test, which is available...

Search